‹³ˆõî•ñ
Ž–¼ ”©ŽR@_l
ƒtƒŠƒKƒi ƒnƒ^ƒPƒ„ƒ}@ƒqƒƒg
E–¼ •‹³
ŠwˆÊ ”ŽŽmi–òŠwj
Œ¤‹†Žº —Տ°–ò—Šwiˆã–òŒn‘‡Œ¤‹†“IA1ŠKj
“d˜b”ԍ† ‚O‚S‚R|‚Q‚Q‚U|‚Q‚W‚V‚X
ƒ[ƒ‹ƒAƒhƒŒƒX h-htakeyama—chiba-u.jp@i—‚Í‘SŠp•\‹Lj
’S“–u‹` –ò•¨Ž¡—ÊwII
¶•¨–òÜŠw/—Տ°–ò—Šw“Á˜_I
ê–啪–ì –ò•¨“®‘ÔŠwAŠà¶•¨ŠwAƒhƒ‰ƒbƒOƒfƒŠƒoƒŠ[ƒVƒXƒeƒ€AƒŠƒ|ƒ\[ƒ€AŠjŽ_ˆã–ò
Œ¤‹†ƒe[ƒ} ‚•ªŽqˆã–ò‚Ì“®‘Ôƒ‚ƒfƒŠƒ“ƒO‰ðÍ‚Æ–òŒøƒƒJƒjƒYƒ€‚̉ð–¾
Žå‚ÈŒ¤‹†‹ÆÑ

Sato Y, Hatakeyama H, Hyodo M, Harashima H. Relationship between the Physicochemical Properties of Lipid Nanoparticles and the Quality of siRNA Delivery to Liver Cells. Mol Ther., in press

Watanabe T*, Hatakeyama H*, Matsuda-Yasui C*, Sato Y*, Sudoh M, Takagi A, Hirata Y, Ohtsuki T, Arai M, Inoue K, Harashima H, Kohara M. In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus. Scientific Reports, 4:4750 (2014)

Wu SY, Yang X, Gharpure KM, Hatakeyama H, et al. 2'-OMe-phosphorodithioate modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat. Commun., 5, 3459 (2014)

Hatakeyama H, Murata M, Sato Y, Takahashi M, Minakawa N, Matsuda A, Harashima H. The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. J. Control. Release, 173: 43-50 (2014)

Hatakeyama H, Akita H, Harashima H. A multifunctional envelope type nano device (MEND) for drug and gene delivery to tumors based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv. Drug Deliv. Rev., 63: 152-160 (2011)

Š‘®Šw‰ï

“ú–{–òŠw‰ï
“ú–{–òÜŠw‰ï
“ú–{ŠàŠw‰ï
“ú–{DDSŠw‰ï

ŠwŠO‚Å‚Ì‹³ˆçEŒ¤‹†Šˆ“®